Skip to main content
OpenTrials
Completed

NCT Number: NCT07340450

Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia

Postpartum anemia is a common condition associated with adverse maternal outcomes. This study aimed to compare the effectiveness of oral iron therapy versus intravenous iron therapy in women with postpartum anemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postpartum Anaemia

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Shahida Islam Medical College and Hospital, Lodhran

Lodhrān, Punjab Province, Pakistan

About this study

This randomized, open-label, parallel-group study was conducted at Shahida Islam Medical College and Hospital, Lodhran, Pakistan. Women diagnosed with postpartum anemia who fulfilled the eligibility criteria were randomly allocated using a lottery method to receive either intravenous iron (ferric carboxymaltose) or oral iron therapy (ferrous sulfate). The primary outcome was the change in hemoglobin level from baseline to 6 weeks of follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All women with postpartum anaemia as per operational definition i.e Haemoglobin <11 g/dl at 24 hours after delivery (either caesarean or SVD).
  • Age 20-40 years.
  • BMI 19-25.
  • Pre-operative haemoglobin >10 g/dl.
  • Both primiparous and multiparous.
  • Both primigravida and multigravida.

-

Exclusion criteria

  • Iron Intolerance or previous history of allergy to iron
  • Parenteral Iron hypersensitivity
  • Patients with thalassemia
  • Indication of blood transfusion
  • Patients with bleeding/ clotting disorders
  • Patients with postpartum haemorrhage
  • Patients with chronic diseases.

Treatment and study plan

Ferric Carboxy Maltose

Drug

Participants received Intravenous iron i.e ferric carboxymaltose (≤1,000 mg) were given to patients in Group "A" either as a single dose or as two doses spaced three days apart in 100 milliliters of 0.9% normal saline during a half-hour period.

Ferrous Sulfate

Drug

Participants given tablet Ferrous sulfate, 325 mg orally three times a day.

Primary outcomes

  1. Change in hemoglobin level

    Time frame: Baseline to 6 weeks postpartum

Sponsors and collaborators

Lead sponsor

Shahida Islam Medical Complex

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 14, 2026
Registry last updated
Jan 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.